JP2012526061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526061A5 JP2012526061A5 JP2012508950A JP2012508950A JP2012526061A5 JP 2012526061 A5 JP2012526061 A5 JP 2012526061A5 JP 2012508950 A JP2012508950 A JP 2012508950A JP 2012508950 A JP2012508950 A JP 2012508950A JP 2012526061 A5 JP2012526061 A5 JP 2012526061A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pain
- group
- drug
- drug addiction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000011117 substance-related disease Diseases 0.000 claims 12
- 208000002193 Pain Diseases 0.000 claims 8
- 206010013663 drug dependence Diseases 0.000 claims 8
- 208000007848 Alcoholism Diseases 0.000 claims 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 6
- 206010013654 Drug abuse Diseases 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 206010020853 Hypertonic bladder Diseases 0.000 claims 4
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 201000007930 alcohol dependence Diseases 0.000 claims 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 208000020629 overactive bladder Diseases 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- RLWGDRLXZSLGHV-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[(4-tert-butylphenyl)methyl]urea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 RLWGDRLXZSLGHV-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 claims 2
- 206010015946 Eye irritation Diseases 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010020843 Hyperthermia Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000004880 Polyuria Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 claims 2
- 108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 206010001584 alcohol abuse Diseases 0.000 claims 2
- 208000025746 alcohol use disease Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 230000001598 anti-natriuretic effect Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 230000007885 bronchoconstriction Effects 0.000 claims 2
- 229960002504 capsaicin Drugs 0.000 claims 2
- 235000017663 capsaicin Nutrition 0.000 claims 2
- 210000000748 cardiovascular system Anatomy 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000035619 diuresis Effects 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 231100000013 eye irritation Toxicity 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 230000036031 hyperthermia Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000007794 irritation Effects 0.000 claims 2
- 238000002690 local anesthesia Methods 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000037023 motor activity Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000002850 nasal mucosa Anatomy 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 claims 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims 2
- 229940073454 resiniferatoxin Drugs 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17627709P | 2009-05-07 | 2009-05-07 | |
| US61/176,277 | 2009-05-07 | ||
| EP09006221.7 | 2009-05-07 | ||
| EP09006221 | 2009-05-07 | ||
| PCT/EP2010/002785 WO2010127855A1 (en) | 2009-05-07 | 2010-05-06 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526061A JP2012526061A (ja) | 2012-10-25 |
| JP2012526061A5 true JP2012526061A5 (https=) | 2015-01-22 |
| JP5767631B2 JP5767631B2 (ja) | 2015-08-19 |
Family
ID=40848721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508950A Expired - Fee Related JP5767631B2 (ja) | 2009-05-07 | 2010-05-06 | バニロイド受容体リガンドとしての置換された芳香族カルボキサミドおよび尿素誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8334315B2 (https=) |
| EP (1) | EP2427436B1 (https=) |
| JP (1) | JP5767631B2 (https=) |
| AR (1) | AR076753A1 (https=) |
| AU (1) | AU2010244684B2 (https=) |
| BR (1) | BRPI1011192A2 (https=) |
| CA (1) | CA2758289A1 (https=) |
| DK (1) | DK2427436T3 (https=) |
| ES (1) | ES2402805T3 (https=) |
| HR (1) | HRP20130128T1 (https=) |
| MX (1) | MX2011011800A (https=) |
| PL (1) | PL2427436T3 (https=) |
| PT (1) | PT2427436E (https=) |
| SI (1) | SI2427436T1 (https=) |
| TW (1) | TWI504589B (https=) |
| WO (1) | WO2010127855A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009067493A2 (en) * | 2007-11-19 | 2009-05-28 | Envivo Pharmaceuticals, Inc. | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
| JP2011507909A (ja) | 2007-12-20 | 2011-03-10 | エンビボ ファーマシューティカルズ インコーポレイテッド | 四置換ベンゼン |
| AU2010244685B2 (en) * | 2009-05-07 | 2016-02-18 | Medifron Dbt Inc. | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| US8946204B2 (en) * | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| HK1198697A1 (en) * | 2011-07-26 | 2015-05-29 | Grünenthal GmbH | Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands |
| BR112014001714A2 (pt) | 2011-07-26 | 2017-02-14 | Gruenenthal Gmbh | derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide |
| CA2848877A1 (en) * | 2011-09-15 | 2013-03-21 | Taipei Medical University | Use of indolyl and indolinvl hvdroxamates for treating heart failure or neuronal injury |
| TW201326135A (zh) | 2011-11-09 | 2013-07-01 | Gruenenthal Gmbh | 以被取代吡唑基甲醯胺及被以一含二氧化硫基團取代之含有一苯基基元之尿素衍生物做為類香草素受體之配位體 |
| WO2013068467A1 (en) | 2011-11-09 | 2013-05-16 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a co-containing group as vanilloid receptor ligands |
| AR088702A1 (es) | 2011-11-09 | 2014-06-25 | Gruenenthal Gmbh | Derivados de carboxamida y urea, basados en pirazolilo sustituido, que presentan una porcion fenilo sustituida con un grupo que contiene o como ligando de receptor vainilloide |
| AU2012334066A1 (en) | 2011-11-09 | 2014-05-22 | Grunenthal Gmbh | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an N-containing group as vanilloid receptor ligands |
| EP2776424A1 (en) | 2011-11-09 | 2014-09-17 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-cyclic group as vanilloid receptor ligands |
| HK1214252A1 (zh) | 2013-03-15 | 2016-07-22 | Verseon Corporation | 作為凝血酶抑制劑的鹵代吡唑 |
| CN110179795A (zh) | 2013-03-15 | 2019-08-30 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途 |
| CN103787895A (zh) * | 2014-01-23 | 2014-05-14 | 安徽华润涂料有限公司 | 一种4-溴-2-甲基苯胺合成的生产工艺 |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| KR102621938B1 (ko) | 2015-01-13 | 2024-01-05 | 닛산 가가쿠 가부시키가이샤 | 반응 혼합물 중의 주석 화합물의 처리 방법 |
| CN107405333A (zh) | 2015-02-27 | 2017-11-28 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| LT3319959T (lt) | 2015-07-06 | 2021-12-27 | Alkermes, Inc. | Histono deacetilazės hetero-halogeno inhibitoriai |
| EP3130590A1 (en) * | 2015-08-13 | 2017-02-15 | Grünenthal GmbH | Aromatic aza compounds as vr1/trpv1 ligands |
| CA3012133A1 (en) | 2016-02-09 | 2017-08-17 | Inventisbio Inc. | Inhibitor of indoleamine-2,3-dioxygenase (ido) |
| EP3241830A1 (de) | 2016-05-04 | 2017-11-08 | Bayer CropScience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN107805221A (zh) * | 2016-09-09 | 2018-03-16 | 西华大学 | 一种制备1h‑吲唑衍生物的方法 |
| US10723723B2 (en) * | 2016-11-03 | 2020-07-28 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors |
| RS62959B1 (sr) | 2017-01-11 | 2022-03-31 | Alkermes Inc | Biciklični inhibitori histon-deacetilaze |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| CN110627683A (zh) * | 2018-06-25 | 2019-12-31 | 广东东阳光药业有限公司 | 一种茚满酮中间体的制备方法 |
| WO2021039023A1 (ja) * | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
| HUE068289T2 (hu) * | 2019-08-23 | 2024-12-28 | Mochida Pharm Co Ltd | Eljárás heterociklidén-acetamid származékok elõállítására |
| CN112409191A (zh) * | 2019-08-23 | 2021-02-26 | 持田制药株式会社 | 光学活性的氨基醇的制备方法 |
| CN118812481A (zh) | 2019-08-23 | 2024-10-22 | 持田制药株式会社 | 杂环亚基乙酰胺衍生物的制造方法 |
| CN110563693B (zh) * | 2019-09-30 | 2022-10-21 | 苏州弘森药业股份有限公司 | 一种胡椒环制备方法 |
| CN115197146A (zh) * | 2021-04-13 | 2022-10-18 | 西格莱(苏州)生物医药有限公司 | 吲唑类化合物的制备方法 |
| WO2024012791A1 (de) | 2022-07-11 | 2024-01-18 | Bayer Aktiengesellschaft | Elektrochemische synthese von pyrazolinen und pyrazolen |
| CN115282134B (zh) * | 2022-07-20 | 2023-06-23 | 天津中医药大学 | 辣椒素在制备治疗脆性x染色体综合征的药物中的应用 |
| TW202506626A (zh) * | 2023-04-25 | 2025-02-16 | 韓商Ｊｗ製藥公司 | 製備４－胺基茚滿之方法及製備二氫茚基－吡唑并［３，４－ｂ］吡啶胺之方法 |
| CN117304009A (zh) * | 2023-10-10 | 2023-12-29 | 韶远科技（上海)有限公司 | 一种3-氟-4-甲基-8-氧代-5,6,7,8-四氢萘的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR230994A1 (es) * | 1981-08-31 | 1984-08-31 | Pfizer | Procedimiento para preparar compuesto de 3'-substituido-5'-(2-amino-4-piridil)-1',2',4'-triazol |
| JPH06157469A (ja) * | 1992-11-13 | 1994-06-03 | Ube Ind Ltd | ピラゾールカルボニルウレア誘導体、その製法及び有害生物防除剤 |
| US6455559B1 (en) | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| US7247748B2 (en) | 2002-03-27 | 2007-07-24 | Smithkline Corporation | Amide compounds and methods of using the same |
| US7393873B2 (en) * | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| US20050192314A1 (en) | 2003-11-13 | 2005-09-01 | Ambit Biosciences Corporation | Urea derivatives as C-kit modulators |
| CN101010315A (zh) | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| DE102005037499A1 (de) | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| JP2009518298A (ja) | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療に有用な尿素化合物 |
| EP2044061A2 (en) * | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| JP2010510202A (ja) * | 2006-11-17 | 2010-04-02 | ファイザー株式会社 | 置換ビシクロカルボキシアミド化合物 |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| WO2008137102A2 (en) * | 2007-05-04 | 2008-11-13 | Torreypines Therapeutics, Inc. | Methods of modulating amyloid beta and compounds useful therefor |
| JP2010083763A (ja) * | 2008-09-29 | 2010-04-15 | Mitsui Chemicals Inc | ピラゾール誘導体およびその製造方法、ならびに殺菌剤 |
-
2010
- 2010-05-06 BR BRPI1011192A patent/BRPI1011192A2/pt not_active IP Right Cessation
- 2010-05-06 US US12/775,155 patent/US8334315B2/en not_active Expired - Fee Related
- 2010-05-06 TW TW099114463A patent/TWI504589B/zh not_active IP Right Cessation
- 2010-05-06 AR ARP100101548A patent/AR076753A1/es unknown
- 2010-05-06 EP EP10720996A patent/EP2427436B1/en not_active Not-in-force
- 2010-05-06 ES ES10720996T patent/ES2402805T3/es active Active
- 2010-05-06 SI SI201030151T patent/SI2427436T1/sl unknown
- 2010-05-06 DK DK10720996.7T patent/DK2427436T3/da active
- 2010-05-06 PT PT107209967T patent/PT2427436E/pt unknown
- 2010-05-06 CA CA2758289A patent/CA2758289A1/en not_active Abandoned
- 2010-05-06 AU AU2010244684A patent/AU2010244684B2/en not_active Ceased
- 2010-05-06 JP JP2012508950A patent/JP5767631B2/ja not_active Expired - Fee Related
- 2010-05-06 WO PCT/EP2010/002785 patent/WO2010127855A1/en not_active Ceased
- 2010-05-06 MX MX2011011800A patent/MX2011011800A/es active IP Right Grant
- 2010-05-06 PL PL10720996T patent/PL2427436T3/pl unknown
- 2010-05-06 HR HRP20130128AT patent/HRP20130128T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526061A5 (https=) | ||
| JP2010523726A5 (https=) | ||
| JP2009500427A5 (https=) | ||
| Ku et al. | Postoperative nausea and vomiting: a review of current literature | |
| TW200738632A (en) | Cannabinoid receptor modulators | |
| JP2008524262A5 (https=) | ||
| GEAP202316320A (en) | Methods and compositions for treating sleep apnea | |
| JP2005531557A5 (https=) | ||
| NO20091251L (no) | Nikotinisk acetylkolinreseptorsubtype selektive amider av diazabicykloalkaner | |
| NZ582056A (en) | Bicyclic heteroaryl compounds for treating conditions related to p2x7 receptor activation | |
| CN106795098B (zh) | α-氨基酰胺衍生化合物及包含其的药物组合物 | |
| JP2011512374A5 (https=) | ||
| RU2014103787A (ru) | Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем | |
| JP2007508361A5 (https=) | ||
| WO2008018827A8 (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
| JP2010510202A5 (https=) | ||
| CN112824399B (zh) | 一种免疫调节剂 | |
| JP2009543825A5 (https=) | ||
| TR201806764T4 (tr) | Yeni benzamid türevi ve bunun kullanımı. | |
| JP2012515150A5 (https=) | ||
| EA201000516A1 (ru) | 3-замещенные 1,2,3-триазин-4-оны и 3-замещенные 1,3-пиримидин-оны для усиления глутаматергических синаптических ответов | |
| JP7167236B2 (ja) | せん妄の予防または治療剤 | |
| MX2009006747A (es) | Formulacion farmaceutica que comprende un antagonista de neurocinina. | |
| WO2016029218A4 (en) | Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation | |
| JP2011515430A5 (https=) |